PGA
ATRS

Premia Global Advisors’s Antares Pharma, Inc. ATRS Stock Holding History

Premia Global Advisors’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-100,000
Closed -$303K – 378
2019
Q1 		$303K Buy
+100,000
New +$324K 0.31% 59

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Premia Global Advisors's ATRS Position: Q2 2019 in Review

Premia Global Advisors sold out of Antares Pharma, Inc. (ATRS) in Q2 2019, closing a stake of 100,000 shares — an estimated $303K sold.

Premia Global Advisors first reported a position in ATRS in Q1 2019 and held it in 1 quarter. The position peaked at $303K in Q1 2019. 127 funds tracked by Wall St. Rank hold ATRS as of Q2 2019.

  • Premia Global Advisors reported no remaining Antares Pharma, Inc. position as of Q2 2019 after selling out during the quarter.
  • Premia Global Advisors sold 100,000 Antares Pharma, Inc. shares in Q2 2019, an estimated $303K.
  • Premia Global Advisors first reported a position in Antares Pharma, Inc. in Q1 2019 and held it in 1 quarter.
  • Premia Global Advisors's Antares Pharma, Inc. position peaked at $303K in Q1 2019.
  • 127 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2019.

Based on Premia Global Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.